Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Kymera Therapeutics (KYMR) Accumulated Depreciation & Amortization (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Accumulated Depreciation & Amortization for 7 consecutive years, with $22.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 37.67% to $22.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.1 million, a 37.67% increase, with the full-year FY2025 number at $22.1 million, up 37.67% from a year prior.
  • Accumulated Depreciation & Amortization was $22.1 million for Q4 2025 at Kymera Therapeutics, down from $22.4 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $22.4 million in Q3 2025 to a low of $3.2 million in Q3 2021.
  • A 5-year average of $11.3 million and a median of $10.4 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: surged 82.39% in 2021, then surged 37.67% in 2025.
  • Kymera Therapeutics' Accumulated Depreciation & Amortization stood at $3.9 million in 2021, then surged by 76.02% to $6.9 million in 2022, then soared by 51.46% to $10.4 million in 2023, then surged by 53.96% to $16.1 million in 2024, then soared by 37.67% to $22.1 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Accumulated Depreciation & Amortization are $22.1 million (Q4 2025), $22.4 million (Q3 2025), and $18.1 million (Q1 2025).